Constitutively activated ERK sensitizes cancer cells to doxorubicin: Involvement of p53-EGFR-ERK pathway (Q38715267)

5 September 2017

title

Constitutively activated ERK sensitizes cancer cells to doxorubicin: Involvement of p53-EGFR-ERK pathway (English)

1 reference

5 September 2017

1 reference

Ratna Kumari

1

1 reference

5 September 2017

Surbhi Chouhan

2

1 reference

5 September 2017

Snahlata Singh

3

1 reference

5 September 2017

Rishi Raj Chhipa

4

1 reference

5 September 2017

Amrendra Kumar Ajay

5

1 reference

5 September 2017

Manoj Kumar Bhat

6

1 reference

5 September 2017

publication date

1 March 2017

1 reference

5 September 2017

published in

Journal of Biosciences

1 reference

5 September 2017

volume

42

1 reference

5 September 2017

issue

1

1 reference

5 September 2017

page(s)

31-41

1 reference

Role of epidermal growth factor receptor degradation in cisplatin-induced cytotoxicity in head and neck cancer

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12038-017-9667-8

Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12038-017-9667-8

Bystander killing of breast cancer MCF-7 cells by MDA-MB-231 cells exposed to 5-fluorouracil is mediated via Fas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12038-017-9667-8

Abrogation of p53 by its antisense in MCF-7 breast carcinoma cells increases cyclin D1 via activation of Akt and promotion of cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12038-017-9667-8

p53 status identifies triple-negative breast cancer patients who do not respond to adjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12038-017-9667-8

The p53 target gene desmocollin 3 acts as a novel tumor suppressor through inhibiting EGFR/ERK pathway in human lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12038-017-9667-8

Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12038-017-9667-8

The role of p53 in chemosensitivity and radiosensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12038-017-9667-8

Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12038-017-9667-8

p53 modulates acquired resistance to EGFR inhibitors and radiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12038-017-9667-8

Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12038-017-9667-8

Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12038-017-9667-8

INK4a/Arf is required for suppression of EGFR/DeltaEGFR(2-7)-dependent ERK activation in mouse astrocytes and glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12038-017-9667-8

Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12038-017-9667-8

Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12038-017-9667-8

MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12038-017-9667-8

Economic downturns, universal health coverage, and cancer mortality in high-income and middle-income countries, 1990–2010: a longitudinal analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12038-017-9667-8

Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor α signalling and results in tamoxifen insensitive proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12038-017-9667-8

Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12038-017-9667-8

TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12038-017-9667-8

Mutant p53 in cancer: new functions and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12038-017-9667-8

DN-R175H p53 mutation is more effective than p53 interference in inducing epithelial disorganization and activation of proliferation signals in human carcinoma cells: role of E-cadherin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12038-017-9667-8

p53 regulates ERK activation in carboplatin induced apoptosis in cervical carcinoma: a novel target of p53 in apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12038-017-9667-8

ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12038-017-9667-8

Cell cycle regulatory protein 5 (Cdk5) is a novel downstream target of ERK in carboplatin induced death of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12038-017-9667-8

Restoration of p53 function leads to tumour regression in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12038-017-9667-8

Requirement for ERK activation in cisplatin-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12038-017-9667-8

Correlation of cellular immunity with human papillomavirus 16 status and outcome in patients with advanced oropharyngeal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12038-017-9667-8

Extracellular signal-regulated kinases modulate DNA damage response - a contributing factor to using MEK inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12038-017-9667-8

EGF receptor and p21WAF1 expression are reciprocally altered as ME-180 cervical carcinoma cells progress from high to low cisplatin sensitivity

21 January 2018

1 reference

12 December 2020

Blockade of the extracellular signal-regulated kinase pathway induces marked G1 cell cycle arrest and apoptosis in tumor cells in which the pathway is constitutively activated: up-regulation of p27(Kip1)

1 reference

12 December 2020

Cell death of MCF-7 human breast cancer cells induced by EGFR activation in the absence of other growth factors

1 reference

12 December 2020

Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA

1 reference

12 December 2020

10.1007/S12038-017-9667-8

Identifiers

DOI

1 reference

Dimensions Publication ID

5 September 2017

1083543005

0 references

1 reference